Target: Nasdaq Capital Market Listing

1. Executive Summary

Bodn Biotech Inc., headquartered in Vancouver, Canada, is pioneering the next generation of protein engineering for animal health. Our flagship program, Porferon, represents a breakthrough in veterinary biologics: the first engineered porcine interferon-like protein with dramatically enhanced antiviral activity compared to natural interferon. Extensive laboratory and early clinical observations show efficacy against PRRSV, ASF, PED, and PRV—diseases that cause billions in economic losses annually.

Beyond Porferon, Bodn Biotech is advancing feline and canine ‘super interferons’ for companion animal health and an IgY antibody platform targeting livestock and pet health. These innovations position us to capture a multi-billion-dollar market across Asia, North America, and Europe.

Our strategy is to commercialize in China first, then expand globally through licensing and partnerships, with the ultimate goal of achieving a Nasdaq Capital Market IPO within five years.

2. Market Opportunity

The global swine industry faces ongoing threats from viral epidemics. China, the world’s largest pork producer with over 700 million pigs, suffers annual losses exceeding RMB 100 billion due to viral diseases. The African Swine Fever outbreak from 2018 to 2019 devastated herds, causing the loss of up to 200 million pigs and over RMB 1 trillion in economic damage.

Globally, viral swine diseases account for direct losses exceeding USD 20 billion per year, with indirect costs from trade restrictions and prevention measures surpassing USD 10 billion.

The companion animal market is another fast-growing segment, fueled by rising pet ownership. Veterinary biologics for cats and dogs are projected to grow at a CAGR of over 10%. Canine parvovirus, feline calicivirus, and distemper remain largely unmet medical needs.

IgY-based products, produced from chicken eggs, offer a natural, resistance-free alternative to antibiotics. The global feed additive market is expected to exceed USD 60 billion by 2030, with IgY antibodies becoming a key component of sustainable farming.

3. Technology & Products

Porferon is engineered via DNA shuffling and directed evolution. Screening over 250,000 clones led to the discovery of a variant that is 131 times more potent against VSV and 1000 times more effective against PRV than natural porcine interferon. It demonstrated 100% protection in PRRSV challenge trials, where untreated pigs showed 80% mortality.

Feline and canine super interferons are species-specific proteins targeting life-threatening viral infections. These biologics represent the first true antiviral biologics in the pet sector, addressing a major unmet need.

Our IgY antibody platform leverages chickens to produce pathogen-specific antibodies at scale. These oral formulations can be integrated into livestock feed, improving immunity, reducing mortality, and replacing antibiotics.

4. Competitive Advantage

Bodn Biotech holds a unique position at the intersection of protein engineering and veterinary health. Our competitive advantages include:
- First-in-class engineered proteins not found in nature.
- Strong IP with patents filed in China and the US.
- Proven track record in drug development: Novaferon, invented by our CEO, became the first Class I new drug for hepatitis B in China in 30 years.
- Diversified pipeline spanning livestock, companion animals, and feed applications.
- Highly experienced scientific and management team with global expertise.

5. Business Model & Strategy

Our commercialization strategy focuses first on the Chinese market, leveraging its large-scale swine industry and rapidly expanding pet sector. Following regulatory approval and market entry, we will expand globally via licensing deals, co-development agreements, and new joint ventures.

Revenue streams include:
- Direct sales of Porferon and pet interferon biologics.
- Licensing of IgY technologies.
- Potential expansion into CDMO/CRDMO services for animal biologics.

We aim to position Bodn Biotech not only as a product company but as a platform provider, offering engineered proteins for multiple applications.

In terms of strategic partnerships, China Animal Husbandry Group has expressed willingness to provide CDMO services for our programs, while a Canadian Indigenous enterprise has shown interest in supporting promotion and market entry in North America. These collaborations will further strengthen our cross-border industrial integration and lay a solid foundation for the global commercialization of Porferon and our broader pipeline.

6. Regulatory Pathway

Porferon will follow veterinary biologic registration pathways under the Ministry of Agriculture in China. Preclinical and safety data will support filings in 2025, with approval anticipated within 3 years. In parallel, filings will be prepared for the US FDA-CVM and EMA.

Feline and canine interferons will undergo veterinary biologics registration in the US and EU, addressing unmet companion animal needs.

IgY products, as feed additives, face fewer regulatory hurdles and can enter markets faster, providing near-term revenue while Porferon undergoes clinical and regulatory development.

7. Financial Plan

We project funding requirements of USD 25–30 million over the next three years. This will cover:
- Completion of Porferon preclinical and clinical programs.
- Advancement of feline and canine interferon programs.
- Scale-up of the IgY platform.

Revenue projections:
- Year 3: Porferon launches in China, generating USD 50M.
- Year 5: Combined sales from pet interferons and IgY exceed USD 150M.
- Year 7: Global expansion drives revenue above USD 500M.

Our long-term vision is a Nasdaq IPO by 2028, backed by strong revenue growth and market leadership.

8. Exit & Nasdaq Listing Strategy

The Nasdaq Capital Market offers an accessible pathway for high-growth biotech firms. Bodn Biotech plans to reach IPO readiness by 2028, once revenue surpasses USD 100M and international expansion is underway.

Key milestones:
- 2025–2026: Porferon preclinical and regulatory submission.
- 2027: Launch IgY feed additive products.
- 2028: IPO preparation and filing.

This exit strategy ensures access to global capital markets, increased visibility, and enhanced credibility with partners and investors.

9. Team

- Dr. Chunsheng Mao, Founder & CEO: Inventor of Novaferon, with over 30 years of experience in biotech.
- Dr. Jianyu Fang: Animal virology expert, 40+ publications, 20+ patents.
- Dr. Shaoyu Li: Director of a leading animal research institute, national awards recipient.

Together, this team combines scientific innovation with proven commercialization expertise.

10. Risks & Mitigation

Key risks include:
- Regulatory risk: Mitigated by early engagement with regulatory bodies in China, US, and EU.
- Scale-up risk: Addressed via partnerships with experienced CDMOs.
- Market adoption: Managed through collaboration with large farms and veterinary clinics to demonstrate early success.
- Competitive risk: Mitigated by strong IP portfolio and first-mover advantage.

11. Appendices

Appendices include:
- Porferon scientific data (in vitro and in vivo).
- Market size breakdown (China, US, EU).
- Patent portfolio summary.
- Detailed financial models and revenue projections.